Novartis AG has agreed to buy U.S. biotech firm Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 ...

Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental ...

With the merger, the Swiss pharmaceutical company aims to bring to more patients farabursen, a kidney-disease treatment ...

The four anti-CD20 drugs used in the U.S. to treat relapsing MS -- ocrelizumab, ofatumumab, and ublituximab (Briumvi; ...

Adding nbUVB phototherapy to oral ritlecitinib improves facial and total body repigmentation in patients with nonsegmental ...

Novartis raised its 2025 outlook after its core operating profit rose 23% on year, boosted by strong demand for its key drugs ...

Swiss pharmaceutical firm Novartis on Tuesday reported better-than-expected first-quarter sales and raised its full-year ...

Despite patent expirations, Novartis' strong cash flow, ongoing buyback, and low-risk profile support our continued buy ...

After announcing successful trial results for its lead mRNA treatment earlier this year, Regulus Therapeutics agreed to be ...

Novartis has agreed to acquire US-based Regulus Therapeutics and its oligonucleotide, farabursen, to bolster its renal ...

Novartis to buy Regulus for $0.8 billion upfront with potential for $1.7B total based on ADPKD drug milestone; deal set to ...

The pharma will pay $800 million for the biotech, which was launched nearly two decades ago by Alnylam and Ionis to advance ...